Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.60), $0.16 better than the analyst estimate of ($1.76). Revenue for the quarter came in at $163.6 million versus the consensus estimate of $146.07 million.

• – Provides 2021 Combined Net Product Revenue Guidance of $610-660 Million, in addition to Collaboration & Royalty Revenue and Operating Expense Guidance –

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.